Outcome and Disease Progression in NYHA Functional Class I and II Patients With Wild-Type Transthyretin Cardiomyopathy Treated With Tafamidis
- PMID: 40609138
- DOI: 10.1016/j.jchf.2025.102549
Outcome and Disease Progression in NYHA Functional Class I and II Patients With Wild-Type Transthyretin Cardiomyopathy Treated With Tafamidis
Keywords: all-cause death; disease progression; heart failure; prognosis; tafamidis; wild-type transthyretin cardiac amyloidosis.
Conflict of interest statement
Funding Support and Author Disclosures Dr Sinigiani is supported by the University of Padua PhD scholarship program, University of Padua, Padua, Italy. Dr Sinigiani has received travel support from Alnylam and Pfizer. Dr Cipriani has received consulting income from AstraZeneca; and has an advisory role for Pfizer, AstraZeneca, and Bayer. Dr Cappelli has received consulting income from AstraZeneca and Bayer; and has an advisory role for Pfizer, AstraZeneca Bayer, Alnylam, Bridgebio, and Amicus. Dr Sinagra has received fees from Biotronik, Boston Scientific, AstraZeneca, and Novartis. Dr Merlo has received fees from Pfizer, Novartis, and Vifor Pharma; and an unrestricted general research grant on amyloidosis by Pfizer, without any control on intellectual contents. Dr Canepa has received speaker and advisor fees in the last 2 years from Akcea Therapeutics, Alnylam, AstraZeneca, Bristol-Myers Squibb, Novartis, Pfizer, and Sanofi Genzyme; and 2 investigator-initiated grants from Pfizer, without any control on intellectual contents. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
LinkOut - more resources
Full Text Sources
Research Materials
